olodaterol
Sign in to saveAlso known as BI-1744-CL, Striverdi®, BI 1744, BI-1744
Olodaterol (trade name Striverdi Respimat) is an ultra-long-acting β adrenoreceptor agonist (ultra-LABA) used as an inhalation for treating people with chronic obstructive pulmonary disease (COPD). It is manufactured by Boehringer Ingelheim.
Research
292 papers- Tiotropium/Olodaterol: A Review in COPD.Drugs · 2019
- Olodaterol.2006
- Olodaterol for the treatment of asthma.Expert opinion on investigational drugs · 2016
- Tiotropium/Olodaterol: A Review in COPD.Drugs · 2016
- Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review.Expert opinion on pharmacotherapy · 2018
via PubMed
~6 min read
Encyclopedic overview
10 sectionsContents
- Medical uses
- Adverse effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Pharmacodynamics
- History
- References
- External links
{{Drugbox | IUPAC_name = 6-hydroxy-8-{(1R)-1-hydroxy-2-{[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino}ethyl}-4H-1,4-benzoxazin-3-one | image = Olodaterol skeletal.svg | image_class = skin-invert-image | width = 275 | alt = | caption = | tradename = Striverdi Respimat | pronounce = Striverdi Respimat | Drugs.com = | MedlinePlus = | pregnancy_AU = B3 | pregnancy_US = C | legal_AU = S4 | legal_CA = | legal_UK = POM | legal_US = Rx-only | legal_status = Rx-only | routes_of_administration = Inhalation (MDI)
| bioavailability = ~30% (inhalation) | protein_bound = ~60% | metabolism = Liver | elimination_half-life = 7.5 hours | excretion = Feces (53%), urine (38%) — following IV administration
Excerpted from Wikipedia’s “olodaterol” article, available under the CC BY-SA 4.0 licence.